Tweet
Both intravesical hyaluronic acid (aka Cystistat) and intravesical chondroitin sulfate (aka Uracyst) are common bladder instillations used in the treatment of IC in Canada and Europe. Why not the USA? The FDA review process is intense AND the studies done here in the USA with these meds have been less than stellar. Will it eventually be approved by the FDA? Not without better studies but the fact remains that research done in other countries continue to show some success and this is, indeed, both positive and encouraging. It's not unusual for patients in the USA to send their prescriptions to pharmacies in Canada to try these medications with, of course, the agreement of their urologists. Here's another study that shows that sodium hyaluronate can be successful! - Jill
Clinical and urodynamic experience with intravesical hyaluronic acid in painful bladder syndrome associated with interstitial cystitis - Abstract
Tue, 26 April 2011
Sección Urología Femenina, División Urología, Facultad de Ciencias Médicas de la Universidade Estadual de Campinas, UNICAMP, Sao Paulo, Brasil.
Few studies have been carried out on therapeutic options in patients with painful bladder syndrome associated with interstitial cystitis. The aim is to verify the safety and effectiveness of treatment with sodium hyaluronate through intravesical instillation in patients with painful bladder syndrome.
A series of 18 female patients is presented, with a mean age of 51 years and prior diagnosis of painful bladder syndrome, who were treated by means of the weekly infusion of an intravesical solution of 40mg of sodium hyaluronate in sterile solution, over a period of eight weeks. The patients were examined clinically and urodynamically prior to their inclusion in the study and eight months after the instillations had concluded.
There was a statistically significant improvement in the urodynamic parameters and in the symptoms measured quantitatively by means of the questionnaire "Pelvic Pain and Urgency/Frequency" between the baseline situation and after the vesical instillation of sodium hyaluronate in patients with painful bladder syndrome. There was no toxicity arising from the treatment, given that no adverse effects were recorded in relation to it.
The clinical use of intravesical hyaluronic acid in patients with painful bladder syndrome possibly associated with interstitial cystitis has been demonstrated.
The clinical improvement is also associated both with increased bladder capacity and improved bladder sensitivity. Tolerance was excellent. Clinical tests that more profoundly evaluate the therapeutic potential of this drug in this type of patients are required.
Article in Spanish.
Written by:
Figueiredo AB, Palma P, Riccetto C, Herrmann V, Dambros M, Capmartin R. Are you the author?
Reference: Actas Urol Esp. 2011 Mar;35(3):184-7.
REPRINTED WITH PERMISSION FROM UROTODAY
Clinical and urodynamic experience with intravesical hyaluronic acid in painful bladder syndrome associated with interstitial cystitis - Abstract
Tue, 26 April 2011
Sección Urología Femenina, División Urología, Facultad de Ciencias Médicas de la Universidade Estadual de Campinas, UNICAMP, Sao Paulo, Brasil.
Few studies have been carried out on therapeutic options in patients with painful bladder syndrome associated with interstitial cystitis. The aim is to verify the safety and effectiveness of treatment with sodium hyaluronate through intravesical instillation in patients with painful bladder syndrome.
A series of 18 female patients is presented, with a mean age of 51 years and prior diagnosis of painful bladder syndrome, who were treated by means of the weekly infusion of an intravesical solution of 40mg of sodium hyaluronate in sterile solution, over a period of eight weeks. The patients were examined clinically and urodynamically prior to their inclusion in the study and eight months after the instillations had concluded.
There was a statistically significant improvement in the urodynamic parameters and in the symptoms measured quantitatively by means of the questionnaire "Pelvic Pain and Urgency/Frequency" between the baseline situation and after the vesical instillation of sodium hyaluronate in patients with painful bladder syndrome. There was no toxicity arising from the treatment, given that no adverse effects were recorded in relation to it.
The clinical use of intravesical hyaluronic acid in patients with painful bladder syndrome possibly associated with interstitial cystitis has been demonstrated.
The clinical improvement is also associated both with increased bladder capacity and improved bladder sensitivity. Tolerance was excellent. Clinical tests that more profoundly evaluate the therapeutic potential of this drug in this type of patients are required.
Article in Spanish.
Written by:
Figueiredo AB, Palma P, Riccetto C, Herrmann V, Dambros M, Capmartin R. Are you the author?
Reference: Actas Urol Esp. 2011 Mar;35(3):184-7.
REPRINTED WITH PERMISSION FROM UROTODAY
Comment